Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Eli Lilly and Company · NCT07258849

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
141
US sites recruiting
9
Study start
December 2, 2025
Record last updated
June 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.

Being studied: LY4213663; LY4213663; Placebo; Placebo

Conditions: Rheumatoid Arthritis (RA)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m²), inclusive

Part C and D Only

  • Have a body weight at least 50 kilograms and BMI within the range 18.0 to 40.0 kg/m² (inclusive) at screening
  • Have a diagnosis of adult-onset RA for at least 3 months prior to screening

Exclusion Criteria

Healthy Participants for SAD Part A and MAD Part B Only:

  • Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs

Participants with RA for Parts C and D Only:

  • Have Class 4 RA according to American College of Rheumatology (ACR) revised criteria
  • Have a 12-lead electrocardiogram (ECG) abnormality at screening
  • Have a current or recent acute active infection

Recruiting US locations

  • Pinnacle Research Group, LLC

    Anniston, AL 36207

    Site contact: 256-236-0055, ext 101

  • Arizona Research Center

    Phoenix, AZ 85053

    Site contact: 602-773-3020

  • Clinical Research of West Florida, Inc. (Clearwater)

    Clearwater, FL 33765

    Site contact: 727-466-0078

  • GNP Research at Mark Jaffe, MD

    Cooper City, FL 33024

    Site contact: 754-248-3589

  • Fortrea Clinical Research Unit

    Daytona Beach, FL 32117

    Site contact: 866-429-3700

  • AGA Clinical Trials

    Hialeah, FL 33012

    Site contact: 704-526-6864

  • Advanced Pharma CR, LLC

    Miami, FL 33417

    Site contact: 305-220-2727, Ext 802

  • Floridian Clinical Research

    Miami Lakes, FL 33016

    Site contact: 305-330-9977

  • Oasis Clinical Research

    Las Vegas, NV 89121

    Site contact: 702-832-1369

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All arthritis studies in Alabama →
A Study of LY4213663 in Healthy Participants and Participants With… (NCT07258849) | Bored Studies